Contact Us
Drug Search Results
More Filters [+]

Radotinib

Alternative Names: radotinib
Latest Update: 2024-10-30
Latest Update Note: Clinical Trial Update

Product Description

Il-Yang Pharm is developing Radotinib as a treatment for chronic myeloid leukemia (CML). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03459534)

Mechanisms of Action: Bcr-Abl Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Il-Yang Pharm
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Radotinib

Countries in Clinic: China, France, Korea, Russia, Turkey, Ukraine

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Chronic Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia

Phase 2: Parkinson's Disease

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
RT51EP1902

P2

Unknown Status

Parkinson's Disease

2026-12-31

RT51KRI03

P3

Recruiting

Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia

2026-06-30

RT51EP1902

P2

Recruiting

Parkinson's Disease

2025-12-31

RT51KR-PK01

P1

Active, not recruiting

Healthy Volunteers

2024-09-03

Recent News Events

Date

Type

Title

04/19/2024

PubMed

 Discovery of common molecular signatures and drug repurposing for COVID-19/Asthma comorbidity: ACE2 and multi-partite networks.

03/26/2024

PubMed

 Hematopoietic cell kinase as a nexus for drug repurposing: implications for cancer and HIV therapy.

11/20/2023

PubMed

 Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors.

04/08/2022

News Article

 Global Chronic Myeloid Leukemia Treatment Market to Surpass US$ 10,864.9 Million by 2028, Says Coherent Market Insights (CMI)

05/10/2021

News Article

 Precipio Launches New HemeScreen Panel for AML, with an unparalleled 4-hour turnaround-time

09/03/2020

News Article

 Small Molecule Cancer Drugs Industry Report 2020-2026 - Clinical Trials Insight on >2,500 Drugs by Phase, Company, Country, Formulation and Indication

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions